BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8689429)

  • 1. Hypertensive reactions associated with paclitaxel.
    Solimando DA; Phillips ET; Weiss RB; Dawson NA; Diehl LF; Rickles NM
    Cancer Invest; 1996; 14(4):340-2. PubMed ID: 8689429
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal chemotherapy for women with breast cancer: the plot thickens.
    Pater JL; Pritchard KI
    J Clin Oncol; 2003 Mar; 21(6):963-4. PubMed ID: 12637457
    [No Abstract]   [Full Text] [Related]  

  • 3. [Taxol in the treatment of ovarian neoplasm].
    Wang Y; Huang R; Huang H
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jul; 34(7):439-41. PubMed ID: 11360659
    [No Abstract]   [Full Text] [Related]  

  • 4. [Paclitaxel].
    Díaz M; Campanero MA
    Rev Med Univ Navarra; 1996; 40(3):43-51. PubMed ID: 9499826
    [No Abstract]   [Full Text] [Related]  

  • 5. [Docetaxel hydrate for treatment of advanced breast cancers].
    Fujii H
    Nihon Rinsho; 2000 Apr; 58 Suppl():254-8. PubMed ID: 11026003
    [No Abstract]   [Full Text] [Related]  

  • 6. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
    Buzdar AU; Singletary SE; Theriault RL; Booser DJ; Valero V; Ibrahim N; Smith TL; Asmar L; Frye D; Manuel N; Kau SW; McNeese M; Strom E; Hunt K; Ames F; Hortobagyi GN
    J Clin Oncol; 1999 Nov; 17(11):3412-7. PubMed ID: 10550135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxol in the management of cancers of the breast and the ovary.
    Khayat D; Antoine EC; Coeffic D
    Cancer Invest; 2000; 18(3):242-60. PubMed ID: 10754992
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS; Kaufman A; Mikhail MM
    Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
    Hudis C; Seidman A; Raptis G; Fennelly D; Gilewski T; Baselga J; Theodoulou M; Sklarin N; Moynahan M; Surbone A; Currie V; Lebwohl D; Uhlenhopp M; Crown J; Norton L
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):58-64. PubMed ID: 8629040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
    Buzdar AU; Singletary SE; Valero V; Booser DJ; Ibrahim NK; Rahman Z; Theriault RL; Walters R; Rivera E; Smith TL; Holmes FA; Hoy E; Frye DK; Manuel N; Kau SW; McNeese MD; Strom E; Thomas E; Hunt K; Ames F; Berry D; Hortobagyi GN
    Clin Cancer Res; 2002 May; 8(5):1073-9. PubMed ID: 12006521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
    Buzdar AU; Hortobagyi GN; Asmar L; Theriault RL; Rahman Z; McNeese M; Singletary S; Ames F
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-31-S17-34. PubMed ID: 9374089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
    Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
    Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
    Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
    Valero V; Hortobagyi GN
    J Clin Oncol; 2003 Mar; 21(6):959-62. PubMed ID: 12637456
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
    Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
    J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Taxol].
    Kühnle H
    Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.